Wall Street is absorbing a jump in retail sales and Jerome Powell's hawkish comments as Trump-fueled optimism starts to wear ...

The MHRA has approved Novavax’s updated Nuvaxovid vaccine for the latest subvariant in individuals aged 12 and older. This ...

Shares of several vaccine makers including Pfizer and Astrazeneca were down Friday morning following the nomination of Robert ...

Powell's hawkish comments are casting a pall on markets as the initial optimism for President-elect Donald Trump's policies starts to wear off. The S&P has already reversed one-third of its ...

The immediate aftermath of the nomination saw vaccine stock prices drop on account of Kennedy’s well-publicized views on ...

Politics will matter greatly for the biotechnology and healthcare sectors. On Thursday, President-elect Trump said that ...

On Wednesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $7.76 which represents a decrease of $-0.70 or -8.27% from the prior close of $8.46. The stock opened at $8.44 and touched a low ...

Shares of BioNTech (BNTX) and Novavax (NVAX) closed with losses of 7%, while Moderna's stock (MRNA) shed 6%. Vaxcyte (PCVX) dropped 4%, and Pfizer (PFE) pulled back 3%. The sizeable declines in these ...

Vaccine stocks continued to fall in premarket trading on Friday, following a sharp decline on Thursday after President-elect Donald Trump announced he would appoint Robert F. Kennedy Jr. to head the ...

BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...